Sabine D. Brookman-May
@brookmans76
Professor of Urology @LMU_Muenchen, Vice President R&D Bladder Cancer, @JNJInnovMed, GU Oncology, Sports Medicine 🚵♀️Passionate Cyclist
ID:1206131683
21-02-2013 22:06:03
1,0K Tweets
2,6K Followers
2,1K Following
15 Posts From ASCO 2024 Day 4 You Should Not Miss!
Karen Knudsen, MBA PhD Zainab Shinkafi-Bagudu Toni Choueiri, MD Andrea Necchi Bishal Gyawali Wafik S. El-Deiry, MD, PhD, FACP Jun Gong Jennifer Marks, MD Yüksel Ürün Sabine D. Brookman-May American Cancer Society Khalid El Bairi Yale Cancer Center Herbert Loong Conquer Cancer, the ASCO Foundation
oncodaily.com/societies/7718…
Excellent coverage on lymph-node only metastatic #UrothelialCancer as a distinct entity among complete responders to Nivo/GC #CheckMate901
➡️Med OS in LN-only mUC: 46.3 (Nivo+GC) vs 24.9 months with GC (HR 0.58)
👉bit.ly/3VtnrVz Matt Galsky UroToday.com OncoDaily
#ASCO24
Updates from the EV-302 study:
Patient reported outcomes indicate meaningful improvements in pain score and overall quality of life favoring EV+P vs. chemotherapy.
Great presentation by Shilpa Gupta !
ASCO Cleveland Clinic
It is an important topic and we need solutions for #ProstateCancer patients how to best reduce hot flashes, anxiety, depression
👉 #PhysicalExercise and #VagusStimulation may be options to explore further
👉Maintenance is key for continuous results, which remains a challenge
Such important work! Use of PPI and antibiotics is associated with worse OS/PFS in patients with #mUC treated with #ICI
Antibiotics have a considerable impact on our immune system. In #cancer care we should even more consider their potential negative impact Shilpa Gupta Charbel Hobeika, MD
Here we go with our Università Vita-Salute San Raffaele medical student Giovanni Pastorino presenting #NureCombo neoadj trial biomarker data. Congratulations the future is bright! Ospedale San Raffaele Chiara Mercinelli Antonio Cigliola Valentina Tateo ASCO #ASCO24 UroToday.com
Tumor fraction and copy number burden using #utDNA may be an excellent biomarker for minimal residual disease #MRD to be used for surveillance in high-risk #NMIBC #BladderCancer
Josh Linscott Roger Li
Tom Powles The question is also which are the parameters + #QoL aspects we need to show differences? What is most important for #patients ? What are the right time points to assess differences over time? Right now we don’t have the perfect tools especially not for early stage GU #cancers
SURE-01: neoadj SG +/- pembro in #MIBC #ASCO24
✅ 36% pCR/45% ypT≤1N0 (RC) + 6/7 pts refusing RC with clinical CR (MRI/cysto/ctDNA/TURBT-)
👉 potential #BladderSparing approach?
🔹Proper AE management required #GCSF
OncoDaily UroToday.com Andrea Necchi Antonio Cigliola ASCO
Chromophobe RCC: Multicenter analysis of 1L systemic therapy options (n=102)
🔹TTF: Longest with VEGF-TKI + mTORi (lenva or beva + everolimus): 17 mo, followed by TKI + IO doublet: 15 mo
🔹OS: Longest with VEGF-TKI + mTORi: 99 mo, followed by TKI + IO doublet: 56 mo
UroToday.com
Great ctDNA work in advanced bladder cancer presented by Tom Powles
Is MRD arriving in advanced disease?
It has been a pleasure to participate in #EAU EAU Young Urologists #TalentIncubator 1 + 2 and to contribute to this publication European Urology
I hope this editorial can provide guidance and kick-off some actions to develop the #urologist of the #future in the best way
authors.elsevier.com/a/1jAJK14kplyy…